Travere Net Profit Margin from 2010 to 2024

TVTX Stock  USD 18.81  0.11  0.59%   
Travere Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to -0.81 in 2024. Net Loss is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(0.77)
Current Value
(0.81)
Quarterly Volatility
1.73161781
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.4 M, Selling General Administrative of 278.8 M or Other Operating Expenses of 548.1 M, as well as many indicators such as Price To Sales Ratio of 6.88, Dividend Yield of 0.0 or PTB Ratio of 3.16. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Net Profit Margin Growth Pattern

Below is the plot of the Net Profit Margin of Travere Therapeutics over the last few years. It is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. Travere Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Profit Margin10 Years Trend
Slightly volatile
   Net Profit Margin   
       Timeline  

Travere Net Profit Margin Regression Statistics

Arithmetic Mean(1.68)
Geometric Mean1.29
Coefficient Of Variation(102.93)
Mean Deviation1.50
Median(0.84)
Standard Deviation1.73
Sample Variance3.00
Range5.1072
R-Value0.66
Mean Square Error1.83
R-Squared0.43
Significance0.01
Slope0.26
Total Sum of Squares41.98

Travere Net Profit Margin History

2024 -0.81
2023 -0.77
2022 -1.31
2021 -0.79
2020 -0.85
2019 -0.84
2018 -0.63

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Net Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(0.77)(0.81)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.